SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-116754
Filing Date
2023-11-13
Accepted
2023-11-13 08:10:23
Documents
14
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2330262d1_8k.htm   iXBRL 8-K 27381
2 EXHIBIT 99.1 tm2330262d1_ex99-1.htm EX-99.1 102540
6 GRAPHIC image_002.jpg GRAPHIC 4572
  Complete submission text file 0001104659-23-116754.txt   323552

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA syn-20231113.xsd EX-101.SCH 3042
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE syn-20231113_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE syn-20231113_pre.xml EX-101.PRE 22378
8 EXTRACTED XBRL INSTANCE DOCUMENT tm2330262d1_8k_htm.xml XML 3324
Mailing Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850
Business Address 9605 MEDICAL CENTER DRIVE SUITE 270 ROCKVILLE MD 20850 (734) 332-7800
Theriva Biologics, Inc. (Filer) CIK: 0000894158 (see all company filings)

IRS No.: 133808303 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12584 | Film No.: 231395289
SIC: 2834 Pharmaceutical Preparations